tiprankstipranks
BioMarin Pharmaceutical (IT:1BMRN)
:1BMRN
Italy Market
1BMRN
BioMarin Pharmaceutical
RESEARCH TOOLSreports

BioMarin Pharmaceutical (1BMRN) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

1BMRN Analyst Ratings

Strong Buy
19Ratings
Strong Buy
15 Buy
4 Hold
0 Sell
Based on 19 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1BMRN Stock 12 Month Forecast

Average Price Target

€79.01
▲(45.08% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is €79.01 with a high forecast of €107.05 and a low forecast of €51.80. The average price target represents a 45.08% change from the last price of €54.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"€44","60":"€60","76":"€76","92":"€92","108":"€108"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107.0454924,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€107.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.01193178421053,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€79.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.796206000000005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€51.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,60,76,92,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.84,56.08657633846154,60.33315267692308,64.57972901538461,68.82630535384615,73.07288169230769,77.31945803076923,81.56603436923078,85.8126107076923,90.05918704615385,94.30576338461537,98.55233972307693,102.79891606153846,{"y":107.0454924,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.84,53.93014859878543,56.020297197570855,58.11044579635628,60.20059439514171,62.29074299392713,64.38089159271256,66.47104019149798,68.56118879028341,70.65133738906883,72.74148598785426,74.83163458663968,76.92178318542511,{"y":79.01193178421053,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.84,51.836631230769235,51.83326246153847,51.8298936923077,51.826524923076924,51.823156153846156,51.81978738461539,51.81641861538462,51.81304984615385,51.809681076923084,51.80631230769231,51.80294353846154,51.79957476923077,{"y":51.796206000000005,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.53,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.84,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€107.05Average Price Target€79.01Lowest Price Target€51.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IT:1BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
€70.79→€75.97
Buy
39.49%
Upside
Reiterated
08/17/26
BioMarin price target raised to $88 from $82 at Piper SandlerBioMarin price target raised to $88 from $82 at Piper Sandler
Barclays Analyst forecast on IT:1BMRN
Eliana Merle
Barclays
Barclays
€90.64→€95.82
Buy
75.95%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stifel Nicolaus Analyst forecast on IT:1BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€60.43
Hold
10.96%
Upside
Reiterated
08/11/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus
Canaccord Genuity Analyst forecast on IT:1BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€95.82→€98.41
Buy
80.71%
Upside
Reiterated
08/10/26
BioMarin price target raised to $114 from $111 at CanaccordBioMarin price target raised to $114 from $111 at Canaccord
Evercore ISI Analyst forecast on IT:1BMRN
Cory Kasimov
Evercore ISI
Evercore ISI
€103.59
Buy
90.22%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cresco Labs (Other OTC: CRLBF)
Morgan Stanley Analyst forecast on IT:1BMRN
Sean Laaman
Morgan Stanley
Morgan Stanley
€102.73→€107.05
Buy
96.56%
Upside
Assigned
08/07/26
Morgan Stanley Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Jefferies Analyst forecast on IT:1BMRN
Akash Tewari
Jefferies
Jefferies
€89.78
Buy
64.86%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on IT:1BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
€64.75→€69.06
Buy
26.81%
Upside
Reiterated
08/07/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo
H.C. Wainwright Analyst forecast on IT:1BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€43.16→€51.8
Hold
-4.89%
Downside
Reiterated
08/07/26
BioMarin price target raised to $60 from $50 at H.C. WainwrightBioMarin price target raised to $60 from $50 at H.C. Wainwright
TD Cowen Analyst forecast on IT:1BMRN
Phil Nadeau
TD Cowen
TD Cowen
€103.59
Buy
90.22%
Upside
Reiterated
08/07/26
TD Cowen Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Oppenheimer Analyst forecast on IT:1BMRN
Leland Gershell
Oppenheimer
Oppenheimer
€82.01→€83.74
Buy
53.76%
Upside
Assigned
08/07/26
BioMarin price target raised to $97 from $95 at OppenheimerBioMarin price target raised to $97 from $95 at Oppenheimer
Raymond James Analyst forecast on IT:1BMRN
Christopher Raymond
Raymond James
Raymond James
€86.33→€90.64
Buy
66.44%
Upside
Reiterated
08/07/26
BioMarin price target raised to $105 from $100 at Raymond JamesBioMarin price target raised to $105 from $100 at Raymond James
RBC Capital Analyst forecast on IT:1BMRN
Luca Issi
RBC Capital
RBC Capital
€53.52
Hold
-1.72%
Downside
Reiterated
08/07/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from RBC Capital
Wedbush Analyst forecast on IT:1BMRN
Yun Zhong
Wedbush
Wedbush
€81.15
Buy
49.00%
Upside
Reiterated
08/07/26
BioMarin Buy Rating Reaffirmed as Strong Voxzogo Performance and Pipeline Progress Support Durable Growth; $94 Price Target Maintained
Bank of America Securities Analyst forecast on IT:1BMRN
Jason Gerberry
Bank of America Securities
Bank of America Securities
€69.06→€74.24
Buy
36.32%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IT:1BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
€70.79→€75.97
Buy
39.49%
Upside
Reiterated
08/17/26
BioMarin price target raised to $88 from $82 at Piper SandlerBioMarin price target raised to $88 from $82 at Piper Sandler
Barclays Analyst forecast on IT:1BMRN
Eliana Merle
Barclays
Barclays
€90.64→€95.82
Buy
75.95%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stifel Nicolaus Analyst forecast on IT:1BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€60.43
Hold
10.96%
Upside
Reiterated
08/11/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus
Canaccord Genuity Analyst forecast on IT:1BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€95.82→€98.41
Buy
80.71%
Upside
Reiterated
08/10/26
BioMarin price target raised to $114 from $111 at CanaccordBioMarin price target raised to $114 from $111 at Canaccord
Evercore ISI Analyst forecast on IT:1BMRN
Cory Kasimov
Evercore ISI
Evercore ISI
€103.59
Buy
90.22%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cresco Labs (Other OTC: CRLBF)
Morgan Stanley Analyst forecast on IT:1BMRN
Sean Laaman
Morgan Stanley
Morgan Stanley
€102.73→€107.05
Buy
96.56%
Upside
Assigned
08/07/26
Morgan Stanley Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Jefferies Analyst forecast on IT:1BMRN
Akash Tewari
Jefferies
Jefferies
€89.78
Buy
64.86%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on IT:1BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
€64.75→€69.06
Buy
26.81%
Upside
Reiterated
08/07/26
BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo
H.C. Wainwright Analyst forecast on IT:1BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€43.16→€51.8
Hold
-4.89%
Downside
Reiterated
08/07/26
BioMarin price target raised to $60 from $50 at H.C. WainwrightBioMarin price target raised to $60 from $50 at H.C. Wainwright
TD Cowen Analyst forecast on IT:1BMRN
Phil Nadeau
TD Cowen
TD Cowen
€103.59
Buy
90.22%
Upside
Reiterated
08/07/26
TD Cowen Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Oppenheimer Analyst forecast on IT:1BMRN
Leland Gershell
Oppenheimer
Oppenheimer
€82.01→€83.74
Buy
53.76%
Upside
Assigned
08/07/26
BioMarin price target raised to $97 from $95 at OppenheimerBioMarin price target raised to $97 from $95 at Oppenheimer
Raymond James Analyst forecast on IT:1BMRN
Christopher Raymond
Raymond James
Raymond James
€86.33→€90.64
Buy
66.44%
Upside
Reiterated
08/07/26
BioMarin price target raised to $105 from $100 at Raymond JamesBioMarin price target raised to $105 from $100 at Raymond James
RBC Capital Analyst forecast on IT:1BMRN
Luca Issi
RBC Capital
RBC Capital
€53.52
Hold
-1.72%
Downside
Reiterated
08/07/26
BioMarin Pharmaceutical (BMRN) Receives a Hold from RBC Capital
Wedbush Analyst forecast on IT:1BMRN
Yun Zhong
Wedbush
Wedbush
€81.15
Buy
49.00%
Upside
Reiterated
08/07/26
BioMarin Buy Rating Reaffirmed as Strong Voxzogo Performance and Pipeline Progress Support Durable Growth; $94 Price Target Maintained
Bank of America Securities Analyst forecast on IT:1BMRN
Jason Gerberry
Bank of America Securities
Bank of America Securities
€69.06→€74.24
Buy
36.32%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
IMRXImmuneering
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Christopher RaymondRaymond James
Success Rate
16/36 ratings generated profit
44%
Average Return
+0.08%
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +0.08% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
22/43 ratings generated profit
51%
Average Return
-2.12%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 51.16% of your transactions generating a profit, with an average return of -2.12% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
18/26 ratings generated profit
69%
Average Return
+1.05%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +1.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1BMRN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
27
26
25
12
Buy
13
11
6
7
5
Hold
6
10
10
13
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
48
42
45
26
In the current month, 1BMRN has received 17 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 1BMRN average Analyst price target in the past 3 months is 79.01.
Each month's total comprises the sum of three months' worth of ratings.

1BMRN Financial Forecast

1BMRN Earnings Forecast

Next quarter’s earnings estimate for 1BMRN is €1.18 with a range of €1.05 to €1.28. The previous quarter’s EPS was €1.04. 1BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1BMRN has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1BMRN is €1.18 with a range of €1.05 to €1.28. The previous quarter’s EPS was €1.04. 1BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1BMRN has Performed in-line its overall industry.

1BMRN Sales Forecast

Next quarter’s sales forecast for 1BMRN is €891.73M with a range of €864.13M to €929.87M. The previous quarter’s sales results were €860.15M. 1BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1BMRN has Performed in-line its overall industry.
Next quarter’s sales forecast for 1BMRN is €891.73M with a range of €864.13M to €929.87M. The previous quarter’s sales results were €860.15M. 1BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1BMRN has Performed in-line its overall industry.

1BMRN Stock Forecast FAQ

What is IT:1BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 79.01.
    What is IT:1BMRN’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 45.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioMarin Pharmaceutical a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Strong Buy, which is based on 15 buy ratings, 4 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s share price target?
            The average share price target for BioMarin Pharmaceutical is 79.01. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €107.05 ,and the lowest forecast is €51.80. The average share price target represents 45.08% Increase from the current price of €54.46.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of BioMarin Pharmaceutical?
                To buy shares of IT:1BMRN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.